ClinicalTrials.gg
CompletedNCT04659317Updated Nov 13, 2026

Opioid-Free Orthopaedics

A Phase 3 interventional study of Oxycodone 5 mg Oral Tablet and Placebo oral tablet in Pain and Pain, Postoperative, sponsored by Emory University. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionPain, PostoperativeRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pain, Postoperative
Why
  1. The study's listed conditions name Pain, Postoperative, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Emory University · Phase 3, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.

Enrollment
693rd of 1,099
56 · median 76
Started
2020
with 85 others
Phase 3
162 of 1,181
18 open now
Registered
777th of 1,181
by date

Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 693rd largest by enrollment of the 1,099 interventional ones that give a count, is one of 86 that started in 2020, is one of 162 in phase 3, and was the 777th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

199 more — sign in →

All 204 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,181 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

The goal of this investigation is to compare effectiveness of this multimodal regimen at controlling postoperative pain with and without the use of opioid medications.

Read the detailed description

Prolonged opioid usage after orthopaedic surgery is an important consideration for both the opioid epidemic and postoperative outcomes. The investigators have developed a multimodal pain control regimen designed to decrease or even potentially eliminate the need for opioids after an orthopedic procedure. This is a prospective double blinded randomized controlled trial utilizing a multimodal pain regimen consisting of education and our standard multimodal pain control regimen. Then, the plan is to randomize patients to receive either encapsulated opioids or placebo. The team will assess patient's pain levels, satisfaction, opioid usage, side effects, patient reported outcomes, and complications. This study will serve as a foundation for future opioid-free surgeries and investigations, while helping to identify patients and factors at risk for prolonged opioid usage postoperatively.

03

Conditions studied

  • Pain
  • Pain, Postoperative

Browse trials for

Keywords

  • Pain management
  • Oxycodone
04

In context

Pain, Postoperative Reclassified

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

This study's enrollment of 56 is below the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.

Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.

Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient with advanced arthritis undergoing a total joint replacement (e.g. total shoulder arthroplasty, anatomic or reverse), in the primary setting.
  • Any patient undergoing an orthopaedic procedure or surgery of their finger, hand, wrist, forearm, or elbow
  • Any patient undergoing an orthopaedic procedure or surgery for their hip, knee, ankle or foot
  • Patients who have exhausted 3+ months of nonoperative treatment to include activity modifications, optional injections, and physical therapy.
  • Patients over the age of 18 years old that are willing to participate in the study and mentally capable to consent

Exclusion criteria

Exclusion Criteria:

  • Patients with concurrent and significant injuries to other bones or organs, local infections, history of alcohol or medical abuse, preoperative opioid use within 3 months of the surgery, advanced renal or liver disease, to receiving a nerve block, uncontrolled diabetes mellitus ( >9.0), or if a prior gastric ulcer precludes Aspirin and anti-inflammatory medications. Prior to inclusion, the patient will undergo blood testing to evaluate both kidney and liver function, including estimated (GFR) as well as (ALT) and aspartate aminotransferase (AST).
  • Workman's compensation status, minors, vulnerable subjects, women who are pregnant, or those who are not willing to consent to participate in the study.
  • Patients who, in the opinion of the investigator, may be non-compliant with study schedules or procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Active comparator
    Opioid Group

    Participants will receive encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed after surgery Safety" Prescription: Oxycodone5 mg po q6 hours as needed for pain

    Drug: Oxycodone 5 mg Oral Tablet

  • Experimental
    Placebo Group

    Participants will receive encapsulated placebo tablets x24, to take po q6 hours as need for pain after surgery "Safety" Prescription: Oxycodone5 mg po q6 hours as needed for pain

    Drug: Placebo oral tablet

Interventions

  • DrugOxycodoneStudies of OxycodoneOxycodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed

  • DrugPlacebo oral tablet

    Encapsulated placebo tablets x24, to take po q6 hours as need for pain

07

What researchers measure

Primary outcomes

  1. Change in Pain (VAS) Score

    The investigators will assess patient postoperative pain utilizing a visual analog scale (VAS) for the first 14 days postoperatively. They will also assess pain at each postoperative visit after at 6 weeks, 3 months, 6 months, 12 months and 24 months. This scale will assess pain at 3 different timepoints throughout the day defined as morning, afternoon, and evening. The pain scale will range from 0-10 with 10 being a worse outcome quantifying the highest pain rating.

    Time frame: Three times a day postoperatively for the first 2 weeks, then 3 months, 6 months, 12 months, and 24 months postoperative

Secondary outcomes

  1. Postoperative Opioid Consumption

    Total opioid consumption in Morphine milligram equivalents (MME) during the first 2 weeks after surgery will be measured.

    Time frame: Postoperative Days 1-14

  2. Number of participants that required Rescue Opioid Prescription

    Number of participants that required the prescribed rescue ("safety") opioid prescription during the first 2 postoperative weeks.

    Time frame: Postoperative Days 1-14

  3. Number of tables consumed as Rescue Opioid

    Number of tablets taken from the prescribed rescue ("safety") opioid prescription during the first 2 postoperative weeks.

    Time frame: Postoperative Days 1-14

  4. Number of Additional Opioid Prescription Refills

    Number of additional opioid prescription refills required during the postoperative period.

    Time frame: Postoperative Days 1-14

  5. Number of participants experiencing Postoperative Nausea

    Number of participants experiencing nausea during the postoperative period. This scale will assess nausea at 3 different timepoints throughout the day defined as morning, afternoon, and evening. The scale will range from 0-10 with 10 being a worse outcome quantifying the highest nausea rating.

    Time frame: Three times a day postoperatively for the first 2 weeks

  6. Hand/Wrist function Measured by the Single Assessment Numeric Evaluation (SANE)

    The Single Assessment Numeric Evaluation (SANE) score requires the patient to rate their injured extremity 0-100 as a percentage of their function compared to normal. A rating of 0 is the minimum value and denotes the worse outcome a patient can have on the scale.

    Time frame: Baseline (Preoperative); and at 3, 6, 12, and 24 months postoperatively.

  7. Upper Extremity Function Measured by the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH)

    Upper extremity disability will be assessed using the QuickDASH questionnaire. Scores range from 0 to 100, with lower scores indicating less disability.

    Time frame: Baseline (Preoperative); and at 12 and 24 months postoperatively.

  8. Overall Satisfaction with the procedure and Pain Management

    Overall satisfaction with the surgical procedure and postoperative pain management will be assessed using a patient-reported 5-point rating scale. Participants will select one of the following responses: "Very satisfied", "satisfied", "neutral", "dissatisfied", and "Very dissatisfied". Responses are assigned a score from 1 to 5, where 1 corresponds to "very dissatisfied" and 5 corresponds to "very satisfied". Higher scores indicate greater satisfaction and better perceived outcomes

    Time frame: 12 and 24 months postoperatively

  9. Willingness to undergo the same procedure with the same pain management

    Number of Participants that confirm their willingness to undergo the same procedure again using the same postoperative pain management regimen.

    Time frame: 12 and 24 months postoperatively

  10. Number of participants Experiencing Major Postoperative Complications

    Number of participants experiencing one or more major postoperative complications, including temporary or permanent nerve injury, hematoma, superficial or deep infection, recurrent moderate or severe pain, fracture, implant loosening, dislocation, or revision surgery.

    Time frame: From surgery through 24 months postoperatively

08

Study locations

3 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jul 2026, 67 months.

Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 67 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2028 → Jul 2026 and completion Dec 2028 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Dec 9, 2020
StartActual
Dec 11, 2020
Primary completionActual
Jul 20, 2026was Dec 2028
CompletionActual
Jul 20, 2026was Dec 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Primary completion
Dec 2028→Jul 20, 2026 (actual)
Nov 13, 2026
Study completion
Dec 2028→Jul 20, 2026 (actual)
Nov 13, 2026
Enrollment
80 (estimated)→56 (actual)
Nov 13, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedPatients with concurrent and significant injuries to other bones or organs, local infections, history of alcohol or medical abuse, preoperative opioid use within 3 months of the surgery, advanced renal or liver disease, contraindication to receiving a nerve block, uncontrolled diabetes mellitus (HbA1C >9.0), or if a prior gastric ulcer precludes Aspirin and anti-inflammatory medications.i. Prior to inclusion, the patient will undergo blood testing to evaluate both kidney and liver function, including estimated glomerular filtration rate (GFR) as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
Nov 13, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameChange in Pain (VAS) ScoreThree times a day postoperatively for the first 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative → Three times a day postoperatively for the first 2 weeks, then 3 months, 6 months, 12 months, and 24 months postoperative
  • DescriptionChange in Pain (VAS) Score: how it is measured was reworded
Nov 13, 2026
Secondary outcomes
3 edited, 7 added, 5 removed
What changed in the outcomes
  • EditedChange in opioid consumptionPostoperative Opioid ConsumptionTime frame: Baseline, 60 months post operative → Postoperative Days 1-14
  • EditedChange inHand/Wrist function Measured by the Single Assessment Numeric Evaluation (SANE) scoreTime frame: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 60 months postoperative → Baseline (Preoperative); and at 3, 6, 12, and 24 months postoperatively.
  • EditedNumber of complicationsparticipants Experiencing Major Postoperative ComplicationsTime frame: End of the trial (up to 60 months post operative) → From surgery through 24 months postoperatively
  • AddedNumber of participants that required Rescue Opioid PrescriptionTime frame: Postoperative Days 1-14
  • AddedNumber of tables consumed as Rescue OpioidTime frame: Postoperative Days 1-14
  • AddedNumber of Additional Opioid Prescription RefillsTime frame: Postoperative Days 1-14
  • AddedNumber of participants experiencing Postoperative NauseaTime frame: Three times a day postoperatively for the first 2 weeks
  • AddedUpper Extremity Function Measured by the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH)Time frame: Baseline (Preoperative); and at 12 and 24 months postoperatively.
  • AddedOverall Satisfaction with the procedure and Pain ManagementTime frame: 12 and 24 months postoperatively
  • AddedWillingness to undergo the same procedure with the same pain managementTime frame: 12 and 24 months postoperatively
  • RemovedChange in patient Satisfaction ScoresTime frame: Three times a day postoperatively for the first 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
  • RemovedChange in associated side effectsTime frame: Postoperatively for the first 14 days, and then 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
  • RemovedChange in American Shoulder and Elbow Surgeons Index Scale (ASES)Time frame: baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months postoperative
  • RemovedChange in European Quality of Life 5 dimension (EQ-5D)Time frame: baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months postoperative
  • RemovedLength of stay postoperativeTime frame: End of the trial (up to 60 months post operative)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Primary completion Dec 2028→Jul 20, 2026 (now actual)
    Study completion Dec 2028→Jul 20, 2026 (now actual)
    Enrollment 80 (estimated)→56 (actual)
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedPatients with concurrent and significant injuries to other bones or organs, local infections, history of alcohol or medical abuse, preoperative opioid use within 3 months of the surgery, advanced renal or liver disease, contraindication to receiving a nerve block, uncontrolled diabetes mellitus (HbA1C >9.0), or if a prior gastric ulcer precludes Aspirin and anti-inflammatory medications.i. Prior to inclusion, the patient will undergo blood testing to evaluate both kidney and liver function, including estimated glomerular filtration rate (GFR) as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameChange in Pain (VAS) ScoreThree times a day postoperatively for the first 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative → Three times a day postoperatively for the first 2 weeks, then 3 months, 6 months, 12 months, and 24 months postoperative
    • DescriptionChange in Pain (VAS) Score: how it is measured was reworded
    Secondary outcomes 3 edited, 7 added, 5 removed
    What changed in the outcomes
    • EditedChange in opioid consumptionPostoperative Opioid ConsumptionTime frame: Baseline, 60 months post operative → Postoperative Days 1-14
    • EditedChange inHand/Wrist function Measured by the Single Assessment Numeric Evaluation (SANE) scoreTime frame: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 60 months postoperative → Baseline (Preoperative); and at 3, 6, 12, and 24 months postoperatively.
    • EditedNumber of complicationsparticipants Experiencing Major Postoperative ComplicationsTime frame: End of the trial (up to 60 months post operative) → From surgery through 24 months postoperatively
    • AddedNumber of participants that required Rescue Opioid PrescriptionTime frame: Postoperative Days 1-14
    • AddedNumber of tables consumed as Rescue OpioidTime frame: Postoperative Days 1-14
    • AddedNumber of Additional Opioid Prescription RefillsTime frame: Postoperative Days 1-14
    • AddedNumber of participants experiencing Postoperative NauseaTime frame: Three times a day postoperatively for the first 2 weeks
    • AddedUpper Extremity Function Measured by the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH)Time frame: Baseline (Preoperative); and at 12 and 24 months postoperatively.
    • AddedOverall Satisfaction with the procedure and Pain ManagementTime frame: 12 and 24 months postoperatively
    • AddedWillingness to undergo the same procedure with the same pain managementTime frame: 12 and 24 months postoperatively
    • RemovedChange in patient Satisfaction ScoresTime frame: Three times a day postoperatively for the first 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
    • RemovedChange in associated side effectsTime frame: Postoperatively for the first 14 days, and then 6 weeks, 3 months, 6 months, 12 months, 24 months, 60 months postoperative
    • RemovedChange in American Shoulder and Elbow Surgeons Index Scale (ASES)Time frame: baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months postoperative
    • RemovedChange in European Quality of Life 5 dimension (EQ-5D)Time frame: baseline (preoperative), 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 60 months postoperative
    • RemovedLength of stay postoperativeTime frame: End of the trial (up to 60 months post operative)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04659317
Lead sponsor
Emory University
Responsible party
Eric Wagner (Assistant Professor, Emory University) — Principal investigator
First posted
Dec 9, 2020
Start date
Dec 11, 2020
Primary completion
Jul 20, 2026
Completion
Jul 20, 2026
Last update
Nov 13, 2026

Study contacts

Eric Wagner, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion